Bionomics Limited (NASDAQ:BNOX) Short Interest Up 101.9% in November

Bionomics Limited (NASDAQ:BNOX) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 384,300 shares, a growth of 101.9% from the October 31st total of 190,300 shares. Based on an average daily volume of 9,290,000 shares, the days-to-cover ratio is currently 0.0 days.

Bionomics Stock Performance

Shares of BNOX remained flat at $0.30 during trading hours on Friday. The company had a trading volume of 266,144 shares, compared to its average volume of 2,968,708. The stock has a 50-day simple moving average of $0.33 and a two-hundred day simple moving average of $0.59. Bionomics has a twelve month low of $0.18 and a twelve month high of $1.60.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Bionomics in a report on Thursday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Bionomics in a research report on Friday, November 15th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new stake in Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.